Full text is available at the source.
Effects of glucagon‐like PEPTIDE‐1 receptor agonists on incidence of hepatocellular carcinoma and liver decompensation in patients with diabetes: A systematic review and META‐analysis
Glucagon-like peptide-1 drugs and their link to liver cancer and liver failure in people with diabetes: A combined study review
AI simplified
Abstract
GLP-1 receptor agonist use is associated with a 58% reduction in hepatocellular carcinoma risk among over 641,377 patients.
- Patients with cirrhosis may experience greater benefits from GLP-1 receptor agonists regarding HCC risk reduction.
- A trend towards reduced liver decompensation risk was noted, but this was not statistically significant.
- The findings suggest a potential role for GLP-1 receptor agonists in strategies for HCC risk assessment and prevention.
AI simplified